'Promising but not perfect': generics industry's take on EMA's literature monitoring service
This article was originally published in SRA
Executive Summary
Generics companies have several reservations about the European Medicines Agency's new literature monitoring service, under which the agency intends to check several reference databases and journals for suspected adverse reactions involving 400 active substances1-3.